GSK in talks to buy cancer biotech Nuvalent for over $9B — FT

• The acquisition price is reported to exceed $9 billion, representing a major investment in GSK's cancer drug pipeline
• Nuvalent is a biotech company focused on developing cancer therapeutics, which would bolster GSK's oncology capabilities
• The talks are ongoing and Reuters has not independently verified the Financial Times report

Summary: GSK in Talks to Acquire Nuvalent for Over $9 Billion

UK pharmaceutical giant GSK is reportedly in advanced negotiations to acquire U.S. cancer biotech company Nuvalent for more than $9 billion, according to a Financial Times report citing sources familiar with the matter.

Key Details

Companies Involved:

• GSK (acquirer): Major UK-based pharmaceutical group
• Nuvalent (target): Cancer-focused drugmaker specializing in oncology therapeutics

Transaction Value: Over $9 billion

Date: Reported June 8, 2025 (per Reuters)

Market Implications

This potential mega-deal would represent a significant strategic move by GSK to bolster its oncology portfolio through acquisition. At over $9 billion, it would rank among the larger pharmaceutical M&A transactions in recent years.

The acquisition would provide GSK with:

• Enhanced presence in the cancer treatment market
• Access to Nuvalent's pipeline of targeted cancer therapies
• Potential revenue diversification in high-growth oncology segment

For the broader pharmaceutical sector, this signals continued consolidation as major players seek to expand therapeutic capabilities and address patent cliffs through strategic acquisitions rather than purely organic R&D development.

Status: Talks are ongoing; Reuters could not independently verify the report at the time of publication.

Investor Considerations: If confirmed, GSK shareholders should monitor deal structure, financing terms, and strategic rationale. Nuvalent stakeholders could see significant premium to current valuation.

This development underscores the pharmaceutical industry's appetite for innovative biotech assets, particularly in oncology, where targeted therapies command premium valuations and offer substantial long-term growth potential.